Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease

Neurochemistry International

Volumn 71, Issue 1, 2014, Pages 36-46

  Ferguson, Marcus C ^a,b   Nayyar, Tultul ^a   Ansah, Twum A ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glutamate; M100907; Microdialysis; MPTP; Parkinsonism; Serotonin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; SEROTONIN; SEROTONIN 2A RECEPTOR; SODIUM CHLORIDE; TETRODOTOXIN; VOLINANSERIN; FLUOROBENZENE; PIPERIDINE DERIVATIVE; SEROTONIN 2 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; HUMAN; IN VIVO STUDY; MALE; MICRODIALYSIS; MOUSE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; UPREGULATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; EXTRACELLULAR SPACE; INTOXICATION; METABOLISM; NEOSTRIATUM; SYNAPTOSOME;

ANIMALS; EXTRACELLULAR SPACE; FLUOROBENZENES; GLUTAMIC ACID; MALE; MICE; MICE, INBRED C57BL; MICRODIALYSIS; MPTP POISONING; NEOSTRIATUM; PARKINSON DISEASE, SECONDARY; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SYNAPTOSOMES;

EID: 84899020554     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2014.03.016     Document Type: Article

References (65)

1. G.K. Aghajanian, and G.J. Marek Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells Neuropharmacology 36 1997 589 599 (Pubitemid 27272104)
2. G.K. Aghajanian, and G.J. Marek Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release Brain Res. 825 1999 161 171 (Pubitemid 29222872)
3. J. Ahlqvist, R. Isacson, C. Wahlestedt, and P. Salmi Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats Eur. Neuropsychopharmacol. 13 2003 177 182 (Pubitemid 36506927)
4. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov. Disord. 16 2001 448 458 (Pubitemid 36041148)
5. P. Anglade, A. Mouatt-Prigent, Y. Agid, and E. Hirsch Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease Neurodegeneration 5 1996 121 128 (Pubitemid 26248601)
6. A. Auclair, G. Blanc, J. Glowinski, and J.P. Tassin Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors J. Neurochem. 91 2004 318 326 (Pubitemid 39363431)
7. M. Bubser, J.R. Backstrom, E. Sanders-Bush, B.L. Roth, and A.Y. Deutch Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum Synapse 39 2001 297 304 (Pubitemid 32128651)
8. C. Chassain, G. Bielicki, E. Durand, S. Lolignier, F. Essafi, A. Traore, and F. Durif Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse J. Neurochem. 105 2008 874 882 (Pubitemid 351562729)
9. E.K. Chung, L.W. Chen, Y.S. Chan, and K.K. Yung Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats J. Comp. Neurol. 511 2008 421 437
10. C. Corsi, A. Pinna, M. Gianfriddo, A. Melani, M. Morelli, and F. Pedata Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats Eur. J. Pharmacol. 464 2003 33 38 (Pubitemid 36205062)
11. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909 (Pubitemid 37130207)
12. P. De Deurwaerdere, and U. Spampinato Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation J. Neurochem. 73 1999 1033 1042 (Pubitemid 29395459)
13. V. Di Matteo, M. Pierucci, E. Esposito, G. Crescimanno, A. Benigno, and G. Di Giovanni Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders Prog. Brain Res. 172 2008 423 463
14. S. Fahn Description of Parkinson's disease as a clinical syndrome Ann. N. Y. Acad. Sci. 991 2003 1 14 (Pubitemid 36793796)
15. M.C. Ferguson, T. Nayyar, A.Y. Deutch, and T.A. Ansah 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease Neuropharmacology 59 2010 31 36
16. F. Galeffi, L. Bianchi, J.P. Bolam, and L. Della Corte The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis Eur. J. Neurosci. 18 2003 856 868 (Pubitemid 37059695)
17. A. Gobert, and M.J. Millan Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats Neuropharmacology 38 1999 315 317 (Pubitemid 29073553)
18. A. Gobert, J.M. Rivet, F. Lejeune, A. Newman-Tancredi, A. Adhumeau-Auclair, J.P. Nicolas, L. Cistarelli, C. Melon, and M.J. Millan Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat Synapse 36 2000 205 221 (Pubitemid 30252995)
19. H.K. Holmer, M. Keyghobadi, C. Moore, and C.K. Meshul L-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neuroscience 136 2005 333 341 (Pubitemid 41483859)
20. P. Huot, T.H. Johnston, L. Winkelmolen, S.H. Fox, and J.M. Brotchie 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA Neurobiol. Aging 33 194 2012 e195-115
21. H.I. Hurtig Problems with current pharmacologic treatment of Parkinson's disease Exp. Neurol. 144 1997 10 16 (Pubitemid 27149595)
22. J. Ichikawa, and H.Y. Meltzer DOI, a 5-HT2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum Brain Res. 698 1995 204 208
23. C.A. Ingham, S.H. Hood, P. Taggart, and G.W. Arbuthnott Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway J. Neurosci. 18 1998 4732 4743 (Pubitemid 28280181)
24. C.A. Ingham, S.H. Hood, B. van Maldegem, A. Weenink, and G.W. Arbuthnott Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway Exp. Brain Res. 93 1993 17 27 (Pubitemid 23104148)
25. N. Jonkers, S. Sarre, G. Ebinger, and Y. Michotte MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats Brain Res. 926 2002 149 155 (Pubitemid 34117600)
26. J.M. Kane Extrapyramidal side effects are unacceptable Eur. Neuropsychopharmacol. 11 Suppl 4 2001 S397 S403
27. T. Kuroki, H.Y. Meltzer, and J. Ichikawa 5-HT 2A receptor stimulation by DOI, a 5-HT 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens Brain Res. 972 2003 216 221 (Pubitemid 36507094)
28. A.E. Lang, and A.M. Lozano Parkinson's disease. First of two parts N. Engl. J. Med. 339 1998 1044 1053 (Pubitemid 28457867)
29. J.C. Lievens, P. Salin, A. Nieoullon, and L. Kerkerian-Le Goff Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA and protein expression in the rat striatum J. Neurochem. 79 2001 893 902 (Pubitemid 33086527)
30. N. Lindefors, and U. Ungerstedt Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons Neurosci. Lett. 115 1990 248 252 (Pubitemid 20231622)
31. G. Lucas, N. Bonhomme, P. De Deurwaerdere, M. Le Moal, and U. Spampinato 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release Psychopharmacology 131 1997 57 63 (Pubitemid 27242855)
32. G. Lucas, and U. Spampinato Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum J. Neurochem. 74 2000 693 701 (Pubitemid 30053742)
33. N.J. Maragakis, and J.D. Rothstein Glutamate transporters: animal models to neurologic disease Neurobiol. Dis. 15 2004 461 473 (Pubitemid 38429961)
34. A. Massie, S. Goursaud, A. Schallier, K. Vermoesen, C.K. Meshul, E. Hermans, and Y. Michotte Time-dependent changes in GLT-1 functioning in striatum of hemi-Parkinson rats Neurochem. Int. 57 2010 572 578
35. A.J. McGeorge, and R.L. Faull The organization of the projection from the cerebral cortex to the striatum in the rat Neuroscience 29 1989 503 537
36. H.Y. Meltzer The mechanism of action of novel antipsychotic drugs Schizophr. Bull. 17 1991 263 287
37. C.K. Meshul, and C. Allen Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion Synapse 36 2000 129 142 (Pubitemid 30196689)
38. C.K. Meshul, J.P. Cogen, H.W. Cheng, C. Moore, L. Krentz, and T.H. McNeill Alterations in rat striatal glutamate synapses following a lesion of the cortico- and/or nigrostriatal pathway Exp. Neurol. 165 2000 191 206
39. C.K. Meshul, N. Emre, C.M. Nakamura, C. Allen, M.K. Donohue, and J.F. Buckman Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion Neuroscience 88 1999 1 16 (Pubitemid 28440387)
40. M.J. Mijnster, A.G. Raimundo, K. Koskuba, H. Klop, G.J. Docter, H.J. Groenewegen, and P. Voorn Regional and cellular distribution of serotonin 5-hydroxytryptamine2a receptor mRNA in the nucleus accumbens, olfactory tubercle, and caudate putamen of the rat J. Comp. Neurol. 389 1997 1 11 (Pubitemid 27476197)
41. C.A. Murphy, and J. Feldon Low-dose clozapine pretreatment partially prevents haloperidol-induced deficits in conditioned active avoidance Behav. Pharmacol. 11 2000 307 316 (Pubitemid 30449762)
42. T. Nayyar, M. Bubser, M.C. Ferguson, M. Diana Neely, J. Shawn Goodwin, T.J. Montine, A.Y. Deutch, and T.A. Ansah Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation Eur. J. Neurosci. 30 2009 207 216
43. J.G. Nutt Levodopa-induced dyskinesia: review, observations, and speculations Neurology 40 1990 340 345 (Pubitemid 20099455)
44. J.G. Nutt, and G.F. Wooten Clinical practice. Diagnosis and initial management of Parkinson's disease N. Engl. J. Med. 353 2005 1021 1027 (Pubitemid 41262336)
45. J.A. Obeso, C.W. Olanow, and J.G. Nutt Levodopa motor complications in Parkinson's disease Trends Neurosci. 23 2000 S2 S7
46. M. Pompeiano, J.M. Palacios, and G. Mengod Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors Brain Res. Mol. Brain Res. 23 1994 163 178
47. G. Porras, V. Di Matteo, C. Fracasso, G. Lucas, P. De Deurwaerdere, S. Caccia, E. Esposito, and U. Spampinato 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum Neuropsychopharmacology 26 2002 311 324 (Pubitemid 34159209)
48. G. Riahi, M. Morissette, M. Parent, and T. Di Paolo Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias Eur. J. Neurosci. 33 2011 1823 1831
49. S. Robelet, C. Melon, B. Guillet, P. Salin, and L. Kerkerian-Le Goff Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease Eur. J. Neurosci. 20 2004 1255 1266 (Pubitemid 39233578)
50. C. Roberts ACP-103, a 5-HT2A receptor inverse agonist Curr. Opin. Investig. Drugs 7 2006 653 660
51. S. Robinson, P. Freeman, C. Moore, J.C. Touchon, L. Krentz, and C.K. Meshul Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function Exp. Neurol. 180 2003 74 87
52. C.J. Schmidt, and G.M. Fadayel Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade J. Pharmacol. Exp. Ther. 277 1996 1541 1549
53. C.J. Schmidt, C.K. Sullivan, and G.M. Fadayel Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine J. Neurochem. 62 1994 1382 1389
54. J.L. Scruggs, S. Patel, M. Bubser, and A.Y. Deutch DOI-Induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons J. Neurosci. 20 2000 8846 8852
55. J.L. Scruggs, D. Schmidt, and A.Y. Deutch The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats Neurosci. Lett. 346 2003 137 140 (Pubitemid 36829280)
56. A.L. Sheldon, and M.B. Robinson The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention Neurochem. Int. 51 2007 333 355 (Pubitemid 47503456)
57. S.M. Sorensen, J.H. Kehne, G.M. Fadayel, T.M. Humphreys, H.J. Ketteler, C.K. Sullivan, V.L. Taylor, and C.J. Schmidt Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies J. Pharmacol. Exp. Ther. 266 1993 684 691 (Pubitemid 23318678)
58. S.K. Suchak, N.V. Baloyianni, M.S. Perkinton, R.J. Williams, B.S. Meldrum, and M. Rattray The 'glial' glutamate transporter, EAAT2 (Glt-1) accounts for high affinity glutamate uptake into adult rodent nerve endings J. Neurochem. 84 2003 522 532 (Pubitemid 36182251)
59. J.L. Taylor, C. Bishop, T. Ullrich, K.C. Rice, and P.D. Walker Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat Neuropharmacology 50 2006 761 768
60. K.E. Vanover, A.J. Betz, S.M. Weber, F. Bibbiani, A. Kielaite, D.M. Weiner, R.E. Davis, T.N. Chase, and J.D. Salamone A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model Pharmacol. Biochem. Behav. 90 2008 540 544
61. R.H. Walker, R.J. Koch, J.E. Sweeney, C. Moore, and C.K. Meshul Effects of subthalamic nucleus lesions and stimulation upon glutamate levels in the dopamine-depleted rat striatum NeuroReport 20 2009 770 775
62. R.P. Ward, and D.M. Dorsa Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum J. Comp. Neurol. 370 1996 405 414 (Pubitemid 26235237)
63. M.J. West, and H.J. Gundersen Unbiased stereological estimation of the number of neurons in the human hippocampus J. Comp. Neurol. 296 1990 1 22 (Pubitemid 20174971)
64. B.H. Westerink, J. Tuntler, G. Damsma, H. Rollema, and J.B. de Vries The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis Naunyn-Schmiedeberg's Arch. Pharmacol. 336 1987 502 507 (Pubitemid 17166839)
65. C.D. Young, M. Bubser, H.Y. Meltzer, and A.Y. Deutch Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation Psychopharmacology 144 1999 255 263 (Pubitemid 29307277)